TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
MWN-AI** Summary
During the "Italy on the Move 2025" side event at the 43rd annual J.P. Morgan Healthcare Conference, over 230 Italian and U.S. executives, investors, and government leaders convened to share insights and successes in the life sciences sector. Organized by the Italian Trade Agency and the Ministry of Foreign Affairs, the event highlighted Italy's robust €270 billion life sciences industry, bolstered by substantial government investment exceeding €2 billion in pharmaceutical R&D in 2023.
Mauro Battocchi, Director General for the Promotion of Italy, emphasized the country's achievements in public health, which have significantly increased the average life expectancy to 83.8 years. This progress is reflective of Italy's strategic positioning as a global leader in life sciences, presenting lucrative investment opportunities.
A panel discussion moderated by Audrey Greenberg featured seven notable life sciences executives who shared their experiences navigating transatlantic partnerships. Participants included Frederick Beddingfield, CEO of Rubedo Life Sciences; Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging; and Elcin Barker Ergun, CEO of Menarini Group, among others. Their collective insights underscored the potential of partnerships between U.S. and Italian firms to drive innovation and growth in the sector.
Additionally, five Italian startups, including Aavantgarde and Medlea, showcased their groundbreaking technologies and investment potential, providing attendees with a glimpse into the future of Italian life sciences.
Trade Commissioner Giosafat Riganò expressed pride in the event's success, noting the impressive turnout and the heightened interest from international investors in Italy's life sciences landscape. This gathering not only reinforced Italy's commitment to fostering innovation but also strengthened cross-border collaborations.
MWN-AI** Analysis
The "Italy on the Move 2025" event, held alongside the J.P. Morgan Healthcare Conference, presented a significant opportunity for investors eyeing the life sciences sector, particularly within Italy’s burgeoning market. With key insights from top Italian and U.S. life sciences executives, it underscored the exciting prospects arising from transatlantic partnerships.
The Italian government’s recent commitment of over €2 billion to pharmaceutical R&D positions the country as a global leader in health innovation, boasting a thriving life sciences sector currently valued at approximately €270 billion. The discussions led by influential figures such as Frederick Beddingfield of Rubedo Life Sciences and Fulvio Renoldi Bracco of Bracco Imaging emphasized the importance of collaborative efforts in navigating this dynamic landscape.
Investors should take stock of the Italian startups highlighted during the event—Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech. These companies are at the forefront of innovation, presenting unique breakthroughs that reflect Italy's strong emphasis on research and development. As the life sciences sector increasingly leans towards digital health technologies and biopharmaceuticals, stakeholders may find substantial opportunities for investment in these burgeoning firms.
The economic narratives shared, particularly by Mauro Battocchi, illustrate how strategic public-private partnerships can elevate market health and accessibility while fostering innovation. Those considering investments should remain vigilant about potential collaborations that align with Italy's regulatory landscape and market needs.
In conclusion, the insights presented at "Italy on the Move 2025" indicate that now could be an opportune moment for investors seeking to capitalize on the Italian life sciences sector's growth, particularly through engagement with innovative startups and established partnerships.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move"
- Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences" panel discussion and five Italian startups pitched their unique breakthroughs and investment opportunities
- Director General for the Promotion of Italy Mauro Battocchi discussed private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1
SAN FRANCISCO , Jan. 28, 2025 /PRNewswire/ -- The Italian Trade Agency (ITA) collaborated with the Ministry of Foreign Affairs and International Cooperation to host the eighth edition of "Italy on the Move," a side event during the 43 rd annual J.P. Morgan Healthcare Conference 2025 at INNOVIT - The Italian Innovation and Culture Hub. The event showcased investment opportunities in Italy in 2025 and included over 230 Italian and U.S. executives, Italian government leaders, members of the scientific and academic world, and investors.
As presented by Mauro Battocchi , Director General for the Promotion of Italy at the Ministry of Foreign Affairs and International Cooperation, following decades of investment by the Italian government in public health, which helped increase the average life expectancy of Italian citizens to 83.8 years and fueled the growth of life sciences businesses in Italy by providing more than € 2 billion on pharma R&D investments in 2023, Italy is now a global leader in life sciences.
The following leaders shared their unique perspectives on investing in Italy during the panel discussion, "Navigating Transatlantic Partnerships in Life Sciences," which was moderated by Audrey Greenberg , Founder of the Center for Breakthrough Medicines and CEO and Founder of AG Capital Advisors.
- Frederick Beddingfield - CEO, Rubedo Life Sciences
- Fulvio Renoldi Bracco - Vice Chairman and CEO, Bracco Imaging
- Elcin Barker Ergun - CEO and Member of the Board, Menarini Group
- Karthic Jayaraman - Partner and Co-Head of Global Healthcare, TPG Capital
- Pierluigi Paracchi - CEO, Co-Founder and Chairman, Genenta Science (Nasdaq: GNTA )
- Maria Cristina Porta - General Director, ENEA Tech and Biomedical
- Riccardo Zagaria - CEO, DOC Pharma
To learn more about the five Italian startups featured in the program, visit their respective websites included below.
Trade Commissioner Giosafat Riganò expressed his enthusiasm for the success of Italy on The Move 2025 , stating: "Thanks to the exceptional efforts of the Italian Trade Agency Team, we witnessed outstanding participation, with over 230 attendees, including U.S. and Italian industry experts, confirming the significant international interest in the Italian Life Sciences industry."
Contact for Future Events and Collaborations:
Italian Trade Agency – Los Angeles Office
losangeles@ice.it
About the Italian Trade Agency
The Italian Trade Agency is the government agency which promotes the globalization of Italian firms under the aegis of the Ministry of Foreign Affairs. ITA helps to develop, facilitate and promote Italian economic and trade relations with foreign countries, focusing on the needs of SMEs, their associations and partnerships. ITA sustains Italian firms in their internationalization process, promoting the marketing of Italian goods and services as well as the image of "Made in Italy" products around the world, while facilitating outward Italian investments and encouraging FDI attraction into Italy. ITA's headquarters are based in Rome, and it works through a large network of offices around the world which are acknowledged as "Trade Promotion Offices" of the Embassies or Consulates of Italy. https://www.ice.it/en/
LinkedIn: https://www.linkedin.com/company/italosangeles/
Twitter: https://twitter.com/ITALosAngeles
Facebook: https://www.facebook.com/italosangeles
About INNOVIT
The Italian Innovation and Culture Hub INNOVIT is a strategic initiative of the Italian Government for the promotion of the Country System's innovation in the United States . Its mission is to foster the Italian innovative companies, startups and tech ecosystems by connecting them with the Silicon Valley and US ones.
Web: innovitsf.com
LinkedIn: innovitsf
1 Assolombarda. (2024, July). La rilevanza della filiera Life Science in Lombardia https://www.assolombarda.it/centro-studi/la-rilevanza-della-filiera-life-science-in-lombardia-edizione-2024 Accessed 1 January 2024 .
SOURCE Italian Trade Agency
FAQ**
What specific business strategies did the executives from Genenta Science S.p.A. (GNTA) identify as critical to fostering partnerships between Italian and U.S. life sciences firms during the "Italy On the Move 2025" event?
How did the recent €2 billion investment in pharma R&D impact companies like Genenta Science S.p.A. (GNTA) and what opportunities does it create for future investments?
In what ways are the breakthroughs presented by Italian startups during the event aligned with the goals of life sciences executives from firms like Genenta Science S.p.A. (GNTA) and their U.S. counterparts?
What lessons did the panelists, including representatives from Genenta Science S.p.A. (GNTA), share about navigating regulatory challenges when establishing transatlantic partnerships in life sciences?
**MWN-AI FAQ is based on asking OpenAI questions about Genenta Science S.p.A. (NASDAQ: GNTA).
NASDAQ: GNTA
GNTA Trading
-6.13% G/L:
$1.99 Last:
533,191 Volume:
$1.97 Open:
